BIRLA INSTITUTE OF TECHNOLOGY, MESRA, RANCHI (END SEMESTER EXAMINATION)

CLASS: BRANCH	M.PHARM I: PHARMACY	SEMESTER : I SESSION : MO/19	
TIME:3:0	SUBJECT: MQA104T PRODUCT DEVELOPMENT & TECHNOLOGY TRANSF DO HOURS	ER FULL MARKS: 75	
INSTRU 1. The 2. Cand 3. The 4. Before 5. Table	CTIONS: question paper contains 7 questions each of 15 marks and total 105 marks. lidates may attempt any 5 questions maximum of 75 marks. missing data, if any, may be assumed suitably. re attempting the question paper, be sure that you have got the correct questio es/Data handbook/Graph paper etc. to be supplied to the candidates in the exam	n paper. iination hall.	
Q.1(a) Q.1(b)	Describe in detail about drug discovery and development with suitable example. What do you mean by NDA? Write about significant parameters of NDA submission.		[7] [8]
Q.2(a) Q.2(b)	Justify the role of IND in drug development process. Explain the role of USFDA in drug regulation.		[7] [8]
Q.3(a)	Discuss the role of pKa and pH in drug absorption of new chemical entities du	ring pre-formulation	[7]
Q.3(b)	studies. Discuss the importance of Noyes-Whitney equation in enhancing the intrinsic disso performing pre-formulation studies of new drug.	lution of drugs while	[8]
Q.4(a)	During intrinsic dissolution studies of new chemical entity, how surface area is he	ld constant. Explain	[7]
Q.4(b)	Explain two-factor simplex optimization to enhance the solubility of new drug w formulation studies.	hile performing pre-	[8]
Q.5(a) Q.5(b)	Define technology transfer and discuss its importance. What do you mean by horizontal and vertical technology transfer? Distinguish betw qualitative technology transfer models.	een quantitative and	[7] [8]
Q.6(a)	What is meant by packaging? What are ideal characteristics of packaging? Expla	n different types of	[7]
Q.6(b)	Explain the different packaging requirements of solid dosage forms.		[8]
Q.7(a) Q.7(b)	Explain QTTP and CQA with reference to scale up? Explain the scale up process of a solid dosage form with an example of scale up op	eration?	[7] [8]

:::::02/12/2019:::::E